IPSC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IPSC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Century Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $2.22 Mil. Century Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $44.25 Mil. Century Therapeutics's annualized EBITDA for the quarter that ended in Mar. 2024 was $-99.34 Mil. Century Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.47.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's
The historical rank and industry rank for Century Therapeutics's Debt-to-EBITDA or its related term are showing as below:
During the past 5 years, the highest Debt-to-EBITDA Ratio of Century Therapeutics was -0.28. The lowest was -0.42. And the median was -0.40.
The historical data trend for Century Therapeutics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Century Therapeutics Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Debt-to-EBITDA | - | -0.42 | -0.28 | -0.41 | -0.40 |
Century Therapeutics Quarterly Data | |||||||||||||||||||
Jun19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Debt-to-EBITDA | Get a 7-Day Free Trial | -0.49 | -0.36 | -0.41 | -0.33 | -0.47 |
For the Biotechnology subindustry, Century Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Century Therapeutics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Century Therapeutics's Debt-to-EBITDA falls into.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Century Therapeutics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (1.513 | + | 46.658) | / | -121.208 | |
= | -0.40 |
Century Therapeutics's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (2.215 | + | 44.251) | / | -99.34 | |
= | -0.47 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.
Century Therapeutics (NAS:IPSC) Debt-to-EBITDA Explanation
In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.
Be Aware
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's
Thank you for viewing the detailed overview of Century Therapeutics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Luis Borges | officer: Chief Scientific Officer | TWO CORPORATE DRIVE, C/O FIVE PRIME THERAPEUTICS, INC., SOUTH SAN FRANCISCO CA 94080 |
Timothy P Walbert | director | 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062 |
Daphne Quimi | director | C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
Versant Venture Capital Vi, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Joseph Jimenez | director | ADITUM BIO, 1111 BROADWAY, STE. 1300, OAKLAND CA 94607 |
Eli Casdin | director | 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019 |
Cynthia M Butitta | director | 3165 PORTER DRIVE, PALO ALTO CA 94304 |
Kimberly Blackwell | director | C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018 |
Rizzuto Carlo | director | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Alessandro Riva | director | C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104 |
Hyam Levitsky | officer: President of R&D | C/O ANTIGENICS INC., 162 FIFTH AVE., SUITE 900, NEW YORK NY 10010 |
Adrienne Farid | officer: Chief Operations Officer | C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104 |
Gregory Russotti | officer: Chief Technology Officer | C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104 |
Osvaldo Flores | officer: Chief Executive Officer | C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104 |
Douglas Carr | officer: VP of Finance and Operations | C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104 |
From GuruFocus
By Stock market mentor Stock market mentor • 02-01-2023
By GuruFocus Research • 11-09-2023
By GuruFocusNews GuruFocusNews • 06-15-2022
By sperokesalga sperokesalga • 04-12-2023
By GuruFocusNews GuruFocusNews • 06-21-2022
By GuruFocusNews GuruFocusNews • 06-26-2022
By Stock market mentor Stock market mentor • 02-08-2023
By GuruFocusNews GuruFocusNews • 06-24-2022
By sperokesalga sperokesalga • 05-11-2023
By PurpleRose PurpleRose • 07-14-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.